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Beneﬁts of Clindamycin
TO THE EDITOR—With great interest we
have read the study by Carapetis et al
[1] about the beneﬁt of clindamycin and
intravenous immunoglobulins, as well as
the risk of disease in close contacts with
patients with invasive group A strepto-
coccal infections. The study indicates im-
proved outcome even after adjustment of
underlying diseases. However, several
limitations of the study were not ade-
quately addressed: (1) The observational
approach limits an in-depth analysis of
the comparison of standard treatment
vs standard treatment plus clindamycin
plus possibly immunoglobulins, as the
authors did not have any inﬂuence of
the choice of treatment. Most important,
only data for antimicrobial therapy are
shown. (2) As mentioned in the accom-
panying editorial [2], early aggressive sur-
gical intervention is critical in cases with
necrotizing fasciitis, but no data about
surgical debridement, which is the single
most important therapy [3], are shown.
Therefore, patients with more severe
group A streptococcal infections might
have beneﬁted from (earlier) surgical de-
bridement, explaining in part the im-
proved outcome in younger patients [4].
(3) Data on underlying comorbidities
are not provided in details, potentially
leading to a bias that is not discussed in
the paper. (4) Current data indicate that
clindamycin should be given prior to
the addition of a β-lactam therapy. The
article does not show any data regarding
the sequence in which the antibiotics
have been administered. In addition,
data on the time to needle—an additional
critical factor for survival—are lacking
[5]. (5) The extrapolation of the risk of
close contacts to the patient population,
namely, a risk >2000-fold that of the
healthy population, lacks sufﬁcient evi-
dence to support routine treatment of
close contacts, as the authors suggest in
the abstract.
We believe that this study provides im-
portant information, and given the rarity
of the disease, a randomized clinical trial
will unlikely be conducted in the close fu-
ture. More observational studies support-
ing the recommendations of the authors
should be conducted before the recom-
mended treatment strategy becomes the
standard.
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